Singapore, Feb. 20 -- ImmunityBio, Inc., a commercial-stage immunotherapy company based in the US, has announced a partnership with Biopharma and Cigalah, two of the largest healthcare commercial and distribution companies in the Middle East, to launch ANKTIVA(R)(nogapendekin alfa inbakicept) in Saudi Arabia and, over time, across the broader MENA region.

Under the agreement, Biopharma and Cigalah Healthcare will support the commercialisation and distribution of ANKTIVA in two indications: In combination with Bacillus Calmette-Guerin (BCG) for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ, with or without papillary disease; and in combination with a checkpoint inhibitor for patients with meta...